An index of some high-impact journals
Selected Publications
2024
Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Tolcher AW, Brody JD, Rajakumaraswamy N, Kuhne M, Trowe T, Dauki AM, Kochikar Pai S, Han L, Lin KW, Petrarca M, Kummar S. Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2808.
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, Thieblemont C, Ursu R, Bartlett NL, Nachar VR, Weiss J, Osterson J, Patel K, Brody JD, Abramson JS, Lunning MA, Shah NN, Ayed A, Kamdar M, Parsons BM, Caimi P, Flynn IW, Herrera AF, Sharman JP, McKenna M, Armand P, Kahl BS, Smith SM, Zelenetz AD, Budde LE, Hutchings M, Phillips TJ, Dickinson M. Blood. 2024 Jan 22:blood.2023022432. doi: 10.1182/blood.2023022432.
T cell states, repertoire and function in classical Hodgkin lymphoma revealed through single-cell analyses. Chen X, Yu J, Venkataraman G, Smith SM, Chen M, Cooper A, Tumuluru S, Brody JD, Godfrey J, Kline J. Cancer Immunol Res. 2024 Jan 19. doi: 10.1158/2326-6066.CIR-23-0547.
2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). Ascierto PA, Avallone A, Bifulco C, Bracarda S, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, Kirchhoff T, Klebanoff CA, Lesinski GB, Monette A, Neyns B, Odunsi K, Paulos CM, Powell DJ Jr, Rezvani K, Segal BH, Singh N, Sullivan RJ, Fox BA, Puzanov I. J Transl Med. 2023 Jul 20;21(1):488. doi: 10.1186/s12967-023-04329-7.
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming. Aleynick M, Svensson-Arvelund J, Pantsulaia G, Kim K, Rose SA, Upadhyay R, Yellin M, Marsh H, Oreper D, Jhunjhunwala S, Moussion CC, Merad M, Brown BD, Brody JD.
J Immunother Cancer. 2023 Jul;11(7):e007198. doi: 10.1136/jitc-2023-007198.
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL. Leuk Lymphoma. 2023 Jan;64(1):130-139. doi: 10.1080/10428194.2022.2136956. Epub 2022 Nov 18.
2022
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Svensson-Arvelund, J., Cuadrado-Castano, S., Pantsulaia, G. et al. Nat Commun 13, 7149 (2022). https://doi.org/10.1038/s41467-022-34791-8. PMID: 36418317
In CAR T cell-treated lymphomas, the T cell rich get richer. Anagnostou T, Brody JD. Nat Med. 2022 Sep;28(9):1757-1758. doi: 10.1038/s41591-022-01922-z. PMID: 36038630.
Cancer vaccines: the next immunotherapy frontier. Lin MJ, Svensson-Arvelund J, Lubitz G, Marabelle A, Melero I, Brown B, Brody JD. Nat Cancer. 2022 Aug;3(8):911-926. doi: 10.1038/s43018-022-00418-6. Epub 2022 Aug 23. PMID: 35999309.
Not just neighbours: positive feedback between tumour-associated macrophages and exhausted T cells. Lubitz GS, Brody JD. Nat Rev Immunol. 2022 Jan;22(1):3. doi: 10.1038/s41577-021-00660-6. PMID: 34789868.
2021
A critical role for fas-mediated off-target tumor killing in T cell immunotherapy. Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Bhalla S, Scholler N, Bot A, Rossi JM, Sadek N, Parekh S, Lagana A, Baccarini A, Merad M, Brown BD, Brody JD. Cancer Discovery, 2021 Mar;11(3):599-613. doi: 10.1158/2159-8290.. PubMed PMID: 33334730.
2020
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL) Xu X, Kalac M, Markson M, Chan M, Brody JD, Bhagat G, Ang RL, Legarda D, Justus SJ, Liu F, Li Q, Xiong H, Ting AT. Cell Death Dis. 2020 Feb 5;11(2):94. doi: 10.1038/s41419-020-2294-6. PubMed PMID: 32024820; PubMed Central PMCID: PMC7002447.
Improving outcomes with checkpoint blockade in non-Hodgkin lymphoma Brody J. Clin Adv Hematol Oncol. 2020 May;18(5):273-275. PubMed PMID: 32628655.
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R. J Exp Med. 2020 Sep 7;217(9). doi: 10.1084/jem.20191712. PubMed PMID: 32558897; PubMed Central PMCID: PMC7478738.
2019
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, Zhan Y, Ostrowski D, Yellin M, Marsh H, Salazar AM, Rahman AH, Brown BD, Merad M, Brody JD. Nat Med. 2019 May;25(5):814-824. doi: 10.1038/s41591-019-0410-x. Epub 2019 Apr 8. PubMed PMID: 30962585.
Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. Aleynick M, Svensson-Arvelund J, Flowers CR, Marabelle A, Brody JD. Clin Cancer Res. 2019 Nov 1;25(21):6283-6294. doi: 10.1158/1078-0432.CCR-18-1800. Epub 2019 May 23. Review. PubMed PMID: 31123052.
Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Marshall N, Hutchinson K, Marron TU, Aleynick M, Hammerich L, Upadhyay R, Svensson-Arvelund J, Brown BD, Merad M, Brody JD. Cancer Discov. 2019 Nov;9(11):1520-1537. doi: 10.1158/2159-8290.CD-19-0391. Epub 2019 Aug 2. PubMed PMID: 31375522; PubMed Central PMCID: PMC6825548.
2018
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. PubMed PMID: 30295695; PubMed Central PMCID: PMC6290929.
2017
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R. Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23. PubMed PMID: 28011673; PubMed Central PMCID: PMC5301824.
2016
In situ vaccination for the treatment of cancer. Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. Immunotherapy. 2016 Mar;8(3):315-30. doi: 10.2217/imt.15.120. PMID: 26860335
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M. Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012. PMID: 27096321
Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Marron TU, Ronner L, Martin PE, Flowers CR, Brody JD. Immunotherapy. 2016 Nov;8(11):1335-1346. doi: 10.2217/imt-2016-0080. Review. PubMed PMID: 27993085.
Lymph nodes can accurately be measured on PET-CT for lymphoma staging/restaging without a concomitant contrast enhanced CT scan. Simpson WL Jr, Lee KM, Sosa N, Cooper N, Scigliano E, Brody JD, Doucette JT, Kostakoglu L. Leuk Lymphoma. 2016 May;57(5):1083-93. doi: 10.3109/10428194.2015.1089437. Epub 2015 Nov 16. PMID: 26422408
2015
DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. Immunity. 2015 Jun 16;42(6):1143-58. doi: 10.1016/j.immuni.2015.05.009. PMID: 26070485
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Hammerich L, Binder A, Brody JD. Mol Oncol. 2015 Dec;9(10):1966-81. doi: 10.1016/j.molonc.2015.10.016. Review. PMID: 26632446
In-situ tumor vaccination: Bringing the fight to the tumor. Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. Hum Vaccin Immunother. 2015;11(8):1901-9. doi: 10.1080/21645515.2015.1049779. Review. PMID: 26055074
Lymphoma: immune evasion strategies. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Cancers (Basel). 2015 Apr 30;7(2):736-62. doi: 10.3390/cancers7020736. Review. PMID: 25941795
Dendritic cells and lymphoma cells: come together right now. Bhardwaj N, Brody JD. Blood. 2015 Jan 1;125(1):5-7. doi: 10.1182/blood-2014-11-606608. No abstract available. PMID: 25554743
Other Publications
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2012 Jan 12;119(2):355-63. PMID: 22045986
Active and passive immunotherapy for lymphoma: proving principles and improving results. Brody J, Kohrt H, Marabelle A, Levy R. J Clin Oncol. 2011 May 10;29(14):1864-75. PMID: 21482977
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. Blood. 2011 Feb 24;117(8):2423-32. Epub 2010 Dec 30. PMID:21193697
Idiotype vaccine strategies for treatment of follicular lymphoma. Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR. Future Oncol. 2011 Jan;7(1):111-22. Review. PMID:21174542
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R. Blood. 2011 Jan 6;117(1):118-27. PMID: 20876455
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010 Oct 1;28(28):4324-32. PMID:20697067
Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Brody J, Levy R. Immunotherapy. 2009 Sep;1(5):809-24. Review. PMID:20636025
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Blood. 2009 Jan 1;113(1):85-94. PMID:18812472
A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma. Knowles JW, Elliott AB, Brody J. Ann Hematol. 2007 Sep;86(9):687-90. PMID:17410366
Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma. Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL. Cancer Genet Cytogenet. 2006 Oct 15;170(2):140-6. PMID: 17011985
Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Ann Hematol. 2006 Nov;85(11):817-20. PMID:16937096
Treatment of mantle cell lymphoma: current approach and future directions. Brody J, Advani R. Crit Rev Oncol Hematol. 2006 Jun;58(3):257-65. Review. PMID:16751087
Using signaling pathways to overcome immune tolerance to tumors. Engleman EG, Brody J, Soares L. Sci STKE. 2004 Jul 6;2004(241):pe28. Review. PMID: 15252217
DC-based cancer vaccines: lessons from clinical trials. Brody JD, Engleman EG. Cytotherapy. 2004;6(2):122-7. Review. PMID: 15203988
CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. Céfaï D, Schneider H, Matangkasombut O, Kang H, Brody J, Rudd CE. J Immunol. 1998 Mar 1;160(5):2223-30. PMID: 9498761